Prognosis of patients with upper tract urothelial carcinoma receiving kidney-sparing therapy
Official title: A Multicenter, Prospective, Observational Clinical Study to Evaluate the Prognosis of Patients With Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy
Run by RenJi Hospital · NCT06204406 · Data updated 2026-11-12
This study looks at how well kidney-sparing treatments work for people with upper tract urothelial carcinoma while avoiding the risks of major surgery.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 106 (estimated) |
| Sponsor | RenJi Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | November 23, 2023 |
| Main results expected | July 1, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | January 12, 2024 |
| Trial ID | NCT06204406 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 90 with histopathologically confirmed upper tract urothelial carcinoma who refuse radical nephroureterectomy or are eligible for kidney-sparing surgery.
✕Probably not a fit
Patients who are unable to undergo kidney-sparing surgery or have a life expectancy of less than six months may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on patients diagnosed with upper tract urothelial carcinoma (UTUC) who are eligible for kidney-sparing therapy. It aims to evaluate the prognosis of these patients while avoiding the complications associated with radical nephroureterectomy, which can lead to impaired renal function. Participants will be monitored over time to assess the effectiveness of kidney-sparing approaches in managing their condition. The study includes patients who have histopathologically confirmed UTUC and are willing to attend follow-up visits.
Why it matters
Potential benefit: If successful, this study could provide insights into effective kidney-sparing treatments for patients with upper tract urothelial carcinoma, potentially improving their quality of life and preserving renal function.
How similar studies have gone: Other studies have shown promising results with kidney-sparing therapies in similar patient populations, indicating that this approach is gaining traction in the management of UTUC.
Who can join: the full rules
Show full inclusion / exclusion criteria
Minimum Age: 18 Years Maximum Age: 90 Years Sex: All Gender Based: No Accepts Healthy Volunteers: No Criteria: Inclusion Criteria: 1. Histopathological confirmed upper tract urothelial carcinoma; 2. Refused radical nephroureterectomy, or eligible for the indications of kidney-sparing surgery; 3. Participants must be willing to attend the follow-up visits; 4. Sign informed consent. Exclusion Criteria: 1. Unable to undergo kidney-sparing surgery; 2. Life expectancy \< 6 months; 3. Previous anti-tumor therapy against UTUC, including systemic chemotherapy, surgery, radiotherapy, or immunotherapy identifying by investigators.
Where it's running
-
Shanghai Renji Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Jiwei Huang, Dr
- Email: jiweihuang@outlook.com
- Phone: 8613651682825
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.